CDC Staff Prohibited From Co-Authoring Papers With World Health Organization Personnel
'CDC staff should not be co-authors on manuscripts/abstracts with WHO staff,' an interim guidance document dated Thursday and obtained by HuffPost says, adding that CDC staff should also not author publications related to work 'funded by WHO.'
Depending on whether CDC staff are the lead authors of a given publication affected by the guidance, they are instructed to either pause all action on the publication or recuse themselves as authors if they cannot pause the publication process.
The guidance also says that manuscripts that do not comply with Trump's executive orders and that were submitted prior to Jan. 20 — the date of Trump's inauguration, and when he moved to withdraw the United States from the WHO — should be withdrawn, or CDC staff should recuse themselves as authors.
'To not only stop all future work but also make people remove their names from papers already in production is full-on Orwellian,' one person familiar with the document told HuffPost.
'It's also not even just for work that WHO funds. If anyone in the list of 20 authors on a paper is WHO-affiliated, you have to get out.'
The interim guidance document was shared with staff Thursday in the CDC's National Center for Immunization and Respiratory Diseases, or NCIRD, and specifically its Influenza Division — but it was worded broadly, referring to CDC staff in general in its body text. It's not clear how many other CDC divisions received the memo.
The influenza division is charged with detecting, preventing and controlling both seasonal and pandemic influenza, both in the United States and around the world. Its scientists study vaccines, detection and pandemic preparedness, and they sequence the genomes of thousands of viruses per year, according to the division's website.
The memo follows a troubling pattern of attacks on science from the Trump administration.
A meeting on Wednesday of a key independent FDA panel focused on this year's flu vaccines was recently abruptly canceled without explanation, for example, prompting frustration and panic.
'I am concerned as it will make it much more difficult for manufacturers to produce an updated influenza vaccine for the 2025-2026 flu season,' one member of the panel, Dr. Anna Durbin of the Johns Hopkins Bloomberg School of Public Health, told HuffPost. 'It is not clear who made the decision to cancel the meeting or why the meeting was canceled.'
The 2024-2025 flu season has been the worst in 15 years.
The Thursday memo followed an earlier instruction that CDC staff should cut off all communication with the World Health Organization, which was reported by CBS News. The Associated Press similarly reported that CDC staff were to stop all work with WHO staff.
On his first day in office, President Donald Trump ordered the United States to withdraw from the World Health Organization, which is a specialized United Nations agency focused on studying, detecting and responding to infectious disease and other public health concerns. Among other things, Trump's executive order directed White House budget officials and the State Department to 'recall and reassign United States Government personnel or contractors working in any capacity with the WHO.'
But it's not just the WHO — across the Trump administration, government scientists face mass layoffs, the erasure of years of data, and the cancellation of important publications and scientific meetings.
Meanwhile, a dangerous bird flu outbreak is spreading among livestock and pets, and a measles outbreak is spreading across Texas.
After a child died of measles in Texas Wednesday — the first U.S. death attributed to the viral infection in a decade — Health Secretary Robert F. Kennedy Jr. minimized and downplayed the news, telling reporters, 'We have measles outbreaks every year.'
The health secretary, who is not a doctor, is 'full of shit,' Rep. Kim Schrier (D-Wash.) told HuffPost. Schrier is a pediatrician.
Pediatrician In Congress Blames RFK Jr. For Child's Death From Measles
RFK Jr. Dismisses Measles Outbreak As 'Not Unusual' After Child's Death
FDA Cancels Meeting With Vaccine Experts, Raising Manufacturing Concerns
'Flu A' Is Surging Right Now. Here's What Alarms Doctors The Most.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
2 hours ago
- CNBC
Investing in Space: NASA's months of reckoning
For half a year now, NASA's been weathering a storm on every front, from its budget to its chain of command and potential program terminations. Employee uproar was an inevitable chapter of the saga. A group of 360 current and former NASA employees have penned a letter rebuking "rapid and wasteful changes" across staffing, mission and budgetary cuts at the space agency. "The last six months have seen rapid and wasteful changes which have undermined our mission and caused catastrophic impacts on NASA's workforce," the letter says, noting concerns that the proposed downsizing in personnel and funding are "arbitrary and have been enacted in defiance of congressional appropriations law" and that "the consequences for the agency and the country alike are dire." Signatories of the letter, titled the Voyager Declaration, urge the U.S. leadership not to implement "harmful" cuts and dispute "non-strategic staffing reductions," curtailing research projects, as well as cancelling contracts and participation in international missions or assignments for which Congress has already appropriated funding. It's no small list of objections raised at a time of broader uncertainty at NASA, which faces significant — and long chronicled — declines in funding and staff, amid a broader White House push to shrink down the federal workforce. "NASA will never compromise on safety. Any reductions—including our current voluntary reduction—will be designed to protect safety-critical roles," NASA Spokesperson Bethany Stevens said in an emailed statement. "The reality is that President Trump has proposed billions of dollars for NASA science, demonstrating an ongoing commitment to communicating our scientific achievements. To ensure NASA delivers for the American people, we are continually evaluating mission lifecycles, not on sustaining outdated or lower-priority missions." Adding to the tumult, NASA on Monday announced the high-level exit of Makenzie Lystrup, who will end her two-year stint as Goddard Space Flight Center director on Aug. 1. NASA says the step was communicated internally before any knowledge of the letter. It's not the first loss from the agency's senior ranks in recent months: Laurie Leshin stepped down from the director post of NASA's Jet Propulsion Laboratory in June. And more exits could be forthcoming: at the start of the month, Politico reported that at least 2,145 senior-level employees could depart NASA, many serving in core mission sets. Throughout, NASA — notable for both its own achievements and its substantial contracts to the U.S. private space industry — has remained without long-term leadership, after U.S. President Donald Trump's initial pick, tech billionaire and Elon Musk ally Jared Isaacman, was unexpectedly removed from consideration back in May. Sean Duffy, Trump's transportation secretary, was appointed to hold up the fort as NASA's interim administrator just this month. Inevitably, there's money on the line. NASA clinched a budget of $24.875 billion last year — 8.5% under its initial request and 2% below the funding of 2023 — that was matched in 2025. Under the Trump administration, the agency battled the possibility of a roughly 25% budget trim in 2026, although the U.S. House of Appropriations subcommittee has pushed back on these cuts. If enacted, the Trump funding proposal of $18.8 billion would have been the smallest NASA budget since before the U.S.' first crewed Moon landing via the Apollo 11 mission, commemorated this week on July 20. In a Monday statement, Trump said his administration is "building on the legacy of Apollo 11" and endorsed NASA's initiatives focused on "returning Americans to the Moon —this time to stay — and putting the first boots on Mars." Colonizing the red planet has been a vocally stated objective of the U.S. president since his January return to office, echoing the ambitions of his then-ally Musk. The two have since parted ways through an explosive rift, but the dream to land U.S. astronauts on the Moon and Mars has gripped the nation, with a respective 67% and 65% of those surveyed in a CBS News/YouGov pollv now in favor.
Medscape
3 hours ago
- Medscape
WHO Issues First Global Arbovirus Guidelines
Arboviral diseases, once mostly found in tropical and subtropical regions, are now spreading worldwide. This growing spread is fueled by climate change, urbanization, population growth, and increased travel. With over 5.6 billion people at risk, the World Health Organization (WHO) has released its first global guidelines for the clinical management of four major arboviral infections: dengue, chikungunya, Zika virus, and yellow fever. The guidance highlights the global spread of Aedes aegypti and Aedes albopictus mosquitoes, the primary vectors for these diseases, which significantly increases the risk for outbreaks in regions where such infections were previously uncommon. Designed to support clinicians, particularly in resource-limited settings, the guidelines provide evidence-based recommendations for diagnosing and managing these infections, where access to laboratory diagnostics and advanced care may be restricted. 'The simultaneous circulation, frequency, and magnitude of outbreaks of these arboviruses are increasing globally, driven by the convergence of ecological, economic, and social factors, with consequent expansion of areas in which cases occur. This increasing incidence in endemic areas and the occurrence of imported and autochthonous (sometimes referred to as indigenous) disease cases in new areas require clinician awareness to recognize the disease and manage cases according to evidence-based guidance, a task complicated by the challenges in differentiating clinically between these infections, particularly in the early phases of illness,' the WHO guidance stated. The new guidelines are based on a thorough systematic review and follow the 2022 handbook developed by the Pan American Health Organization, based in Washington, DC, the regional office of the WHO for the Americas. While the 2022 handbook focused on arboviral disease management in the Americas, a group of international experts revised and expanded the guidelines to address global needs. One of the key challenges highlighted in the new WHO guidelines is the difficulty in distinguishing between arboviral infections in regions where multiple arboviruses may circulate simultaneously, making clinical differentiation challenging, particularly where diagnostic testing is not readily available. Because early symptoms often overlap, WHO guidelines emphasize the need for laboratory confirmation while also providing clinical features to help differentiate between arboviral infections during the initial diagnosis. Dengue, the most prevalent arboviral infection, is typically marked by thrombocytopenia (low platelet count), progressive increase in hematocrit, and leukopenia. These are key clinical indicators of disease severity. In chikungunya, persistent arthralgia (joint pain) is the most prominent distinguishing feature. Pruritus (itching) is more commonly observed in Zika infections. The WHO guidelines present comprehensive recommendations for treating these diseases based on disease severity, dividing cases into nonsevere and severe. For patients with suspected or confirmed nonsevere dengue, chikungunya, Zika, or yellow fever, the WHO recommends oral rehydration using small and frequent sips throughout the day. Paracetamol or dipyrone is advised for managing pain and fever. The use of corticosteroids is not recommended in nonsevere cases. Nonsteroidal anti-inflammatory drugs should be avoided regardless of disease severity. For hospitalized patients with suspected or confirmed severe arboviral disease, the WHO provides detailed clinical guidance, including. Prefer crystalloid fluids over colloids for intravenous (IV) rehydration. Monitor IV fluid management using capillary refill time. Measure serum lactate levels as part of IV fluid decision-making. Use a passive leg raise test in patients in shock when the clinician is unsure about the need to administer more IV fluids. Avoid systemic corticosteroids and immunoglobulins. Avoid prophylactic platelet transfusions in patients with platelet counts < 50,000/μL unless active bleeding.
Yahoo
4 hours ago
- Yahoo
Wells Fargo Cuts Elevance (ELV) Price Target on Margin Uncertainty
Elevance Health, Inc. (NYSE:ELV) ranks among the . Wells Fargo kept its Overweight rating on Elevance Health, Inc. (NYSE:ELV) on July 15, but lowered its price target on the health insurer from $478 to $400. Wells Fargo applied a lower multiple of 10.5x to its 2026 earnings per share projection of $38.05, which is less than the previous multiple of 11.5x. designer491/ Wells Fargo stated that the primary driver of the reduced value multiple was uncertainty regarding margins in the Medicaid, Medicare Advantage (MA), and Health Insurance Exchange (HIX) segments for 2025. The firm also pointed out that there was 'relatively low visibility to improvement in 2026,' especially in the Medicaid and Health Insurance Exchange segments. However, it insisted that Elevance's valuation 'remains compelling once dust settles on estimates.' Elevance Health, Inc. (NYSE:ELV), previously Anthem, Inc., is a leading health-benefits provider in the United States. The company offers medical, pharmaceutical, dental, long-term care, disability, and behavioral health insurance under numerous brands, including Anthem Blue Cross, Blue Shield, Wellpoint, and Carelon. While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
